Value of PCR, Serology, and Blood Smears for Human Granulocytic Anaplasmosis Diagnosis, France
Yves Hansmann

, Benoit Jaulhac, Pierre Kieffer, Martin Martinot, Elisabeth Wurtz, Régis Dukic, Geneviève Boess, André Michel, Christophe Strady, Jean François Sagez, Nicolas Lefebvre, Emilie Talagrand-Reboul, Xavier Argemi, and Sylvie De Martino
Author affiliations: Université de Strasbourg, Strasbourg, France (Y. Hansmann, B. Jaulhac, E. Talagrand-Reboul, S. De Martino); Hôpitaux Universitaires de Strasbourg, Strasbourg (Y. Hansmann, N. Lefebvre, X. Argemi); Centre National de Référence des Borrelia, Strasbourg (B. Jaulhac, S. De Martino); Centre Hospitalier Emile Muller, Mulhouse, France (P. Kieffer); Centre Hospitalier Pasteur, Colmar, France (M. Martinot); Centre Hospitalier Saverne, Saverne, France (E. Wurtz); Centre Hospitalier de Haguenau, Haguenau, France (R. Dukic); Centre Hospitalier de Guebwiller, Guebwiller, France (G. Boess); Centre Hospitalier de Wissembourg, Wissembourg, France (A. Michel); Polyclinique Saint André, Reims, France (C. Strady); Centre Hospitalier Sélestat, Sélestat, France (J.F. Sagez)
Main Article
Figure
Figure. Distribution of positive diagnostic test results for patients with confirmed human granulocytic anaplasmosis, France, May 2010–July 2012.
Main Article
Page created: April 17, 2019
Page updated: April 17, 2019
Page reviewed: April 17, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.